Fedotev; Boris
Patent Applications and Registrations
Patent applications and USPTO patent grants for Fedotev; Boris.The latest application filed is for "candesartan cilexetil polymorphs".
- Fedotev; Boris - Haifa IL
| Patent | Date |
|---|---|
| Candesartan cilexetil polymorphs App 20100121072 - Etinger; Marina Yu ; et al. | 2010-05-13 |
| Candesartan cilexetil polymorphs Grant 7,692,023 - Etinger , et al. April 6, 2 | 2010-04-06 |
| Preparation of candesartan cilexetil App 20060252939 - Etinger; Marina Yu ; et al. | 2006-11-09 |
| Preparation of candesartan cilexetil Grant 7,098,342 - Etinger , et al. August 29, 2 | 2006-08-29 |
| Preparation of candesartan cilexetil in high purity App 20050250827 - Etinger, Marina Yu ; et al. | 2005-11-10 |
| Candesartan cilexetil polymorphs App 20050250828 - Etinger, Marina Yu ; et al. | 2005-11-10 |
| Process for production of highly pure donepezil hydrochloride App 20050239837 - Gutman, Arie L. ; et al. | 2005-10-27 |
| Preparation of candesartan cilexetil App 20050131037 - Etinger, Marina Yu ; et al. | 2005-06-16 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 